AD981

Phase 2Small molecule

IIstituto Auxologico Italiano

AD981 is one of 4 small molecule programs targeting Hypoventilation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoventilationActive, not recruiting

HypoventilationPhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Hypoventilation

#DrugCompanyPhaseTrials

Desogestrel

MMahidol University

Phase 2

1 2

Ketalar

AAultman Health Foundation

Preclinical

2 3

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 4

AD981

IIstituto Auxologico Italiano

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoventilation1 trial

Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome

Completed·IIstituto Auxologico Italiano·Phase 2·NCT05448443·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AD981. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AD981 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AD981. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Istituto Auxologico Italiano company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIstituto Auxologico Italiano

AD981

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoventilation1 trial

References

Drug Info

Quick Facts

Related News